Presented at the ACMT Annual Scientific Meeting 2023 – San Diego, CA

Published in J Med Toxicol 2023;19(2):142-143.

167. Adverse Drug Events Associated With Remdesivir Among Hispanic Populations

Michael Levine1, Anthony F. Pizon2, Katie Boyle3, Evan Schwarz1,4, Kapil Sharma5, Jennifer Carey6, Maryann Amirshahi7, Robert Hendrickson8, Travis Olives9, Kennon Heard10, Jeffrey Brent10, Eric Lavonas11, Paul Wax12, Jason Devgun4, Ziad Kazzi13, Michael Chary14, Jonathan Schimmel15, Meghan Spyres16, Kim Aldy12, Timothy Wiegand17, Michael Marlin18, Sophia Shiekh19, Tony Rianprakaisang20; On Behalf of the ToxIC FACT Study Group

1University of California, Los Angeles, Los Angeles, CA. 2University of Pittsburgh, Pittsburgh, PA. 3Beth Israel Deaconess Medical Center, Boston, MA. 4Washington University, St. Louis, MO. 5University of Texas, Southwestern, Dallas, TX. 6University of Massachusetts, Worcester, MA. 7Medstar Washington Hospital, Washington DC. 8Oregon Health Science University, Portland, OR. 9Hennepin County Medical Center, Minneapolis, MN. 10University of Colorado, Denver, CO. 11Denver Health, Denver, CO. 12American College of Medical Toxicology, Phoenix, AZ. 13Emory University, Atlanta, GA. 14Cornell University, New York, NY. 15Mt Sinai Medical Center. 16Banner University Medical Center – Phoenix. 17University of Rochester, Rochester, NY. 18University of Mississippi, Jackson, MS. 19University of Florida – Jacksonville, Jacksonville, FL. 20University of Kansas, Kansas City, KS.

Background: Genetic differences in drug metabolism have been identified for many drugs among different races and ethnicities. Such altered metabolism may be responsible for different rates of adverse drug events (ADEs). It has been suggested that Hispanic individuals may have higher rates of ADEs related to remdesivir, although data supporting such a claim is lacking.

Hypothesis/Aims: This study attempted to evaluate if there are different rates of ADEs among Hispanic individuals receiving remdesivir compared to non-Hispanic individuals.

Methods: The FDA-ACMT Covid-19 ToxIC (FACT) pharmacovigilance project both retrospectively and prospectively entered possible ADEs related to prevention and treatment of covid-19. A total of 17 hospitals submitted cases between 11/23/2020 through 9/30/2022. All cases of ADEs associated with remdesivir were examined. A risk ratio was calculated for cases of ADEs associated with remdesivir based on Hispanic or non-Hispanic ethnicity. Logistic regression was performed to adjust for sex and age.

Results: The median (IQR) age was 61 (49-71) years; 58% were male. 180 Hispanic individuals were identified in the cohort of ADEs. 543 ADEs reported with remdesivir, including 234 cases of bradycardia, and 171 cases of hepatotoxicity. After adjusting for age and sex, there was no difference in the rates of overall ADEs with remdesivir. Specifically, there were no differences in the overall rates of ADEs, nor was there any difference in the rates of bradycardia or hepatotoxicity in Hispanic individuals compared with non-Hispanic individuals.
Conclusion: This study did have several limitations, including possibly being under powered to detect subtle differences. Ethnicity reporting was based on retrospective review, with such inherent limitations, possibly resulting in misclassification. Nonetheless, in this series, there is no observed difference in the rates of ADEs associated with remdesivir among Hispanic individuals compared with non-Hispanic individuals.